More deaths occurred in patients treated with aprotinin than in those treated with two other blood-loss-limiting drugs -- aminocaproic acid and tranexamic acid.
The scientists concluded that 10,000 deaths could have been avoided over the five-year period "had aprotinin been replaced with either of these generic agents."
The report is published in the Feb. 7 issue of The Journal of the American Medical Association.
bypass, surgery, coronary, death, blood loss, side effects, aprotinin, aminocaproic acid, tranexamic acid, health, heart disease,
No comments:
Post a Comment